Arbutus Biopharma Corp (ABUS) - News Archive

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company renowned for its innovative approaches to virology, has announced its participation in the H.C. Wainwright @ Home virtual fireside...

Promising Advances in HBV Treatment: Arbutus Imdusiran and Interferon Combine for Transformative Patient Outcomes In recent developments within the realm of hepatitis B virus (HBV) treatment, Arbutus Biopharma s investi...

Treatment with Arbutus Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg LevelsData highlighted in oral presentation at the European Association for the Study of the Liver (EASL) CongressArbutus...

In the field of Hepatitis B Virus (HBV) research, one of the major challenges has been achieving sustained undetectable levels of Hepatitis B surface antigen (HBsAg), which is considered a crucial requirement for functi...

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company specializing in virology, has recently announced a significant development in its ongoing patent infringement lawsuit against Moderna, Inc. In co...

Arbutus Biopharma Corp: Charting a Bright Future with Groundbreaking RNAi TherapeuticArbutus Biopharma Corp, a leading biotechnology company, has recently unveiled its ambitious corporate objectives for 2024, along with...